Gain Therapeutics is trading 8.67% higher at $1.25 after a sharp rebound following its regular-session decline; no clear company-specific catalyst has been identified. - It closed at $1.15 on October 26. - The latest located announcements were an October 8 notice about attending the Maxim Growth Summit and an October 1 clinical-trial update; neither is a new October 26 announcement explaining the move. - Major U.S. indexes finished higher, but gains were modest, leaving a broader-market explanation uncertain.